Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Econor
1. Econor
2. 101312-92-9
3. 2ahc415bqg
4. [(1s,2r,3s,4s,6r,7r,8r,14r)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[[(2r)-2-amino-3-methylbutanoyl]amino]-2-methylpropan-2-yl]sulfanylacetate
5. Acetic Acid,[[2-[[(2r)-2-amino-3-methyl-1-oxobutyl]amino]-1,1-dimethylethyl]thio]-,(3as,4r,5s,6s,8r,9r,9ar,10r)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-ylester
6. Valnemulin [inn:ban]
7. Unii-2ahc415bqg
8. Ncgc00167968-01
9. Valnemulin [mi]
10. Valnemulin [mart.]
11. Dsstox_cid_26751
12. Dsstox_rid_81876
13. Dsstox_gsid_46751
14. Schembl216709
15. Chembl1688852
16. Dtxsid2046751
17. (hydroxy-tetramethyl-oxo-vinyl-[?]yl) 2-[2-[[(2r)-2-amino-3-methyl-butanoyl]amino]-1,1-dimethyl-ethyl]sulfanylacetate
18. Tox21_112596
19. Zinc30727788
20. Valnemulin [ema Epar Veterinary]
21. ((2-((r)-2-amino-3-methylbutyramido)-1,1-dimethylethyl)thio)acetic Acid, 8-ester With (3as,4r,5s,6s,8r,9r,9ar,10r)-octahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one
22. Cas-101312-92-9
23. Ab01566922_01
24. Q7912519
| Molecular Weight | 564.8 g/mol |
|---|---|
| Molecular Formula | C31H52N2O5S |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 10 |
| Exact Mass | 564.35969394 g/mol |
| Monoisotopic Mass | 564.35969394 g/mol |
| Topological Polar Surface Area | 144 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 969 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
* Pigs:
The treatment and prevention of swine dysentery. The treatment of clinical signs of porcine proliferative enteropathy (ileitis). The prevention of clinical signs of porcine colonic spirochaetosis (colitis) when the disease has been diagnosed in the herd. Treatment and prevention of swine enzootic pneumonia. At the recommended dosage of 1012 mg/kg bodyweight lung lesions and weight loss are reduced, but infection with Mycoplasma hyopneumoniae is not eliminated.
* Rabbits:
Reduction of mortality during an outbreak of epizootic rabbit enteropathy (ERE). Treatment should be started early in the outbreak, when the first rabbit has been diagnosed with the disease clinically.
QJ01XQ02
ABOUT THIS PAGE
A Valnemulin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Valnemulin, including repackagers and relabelers. The FDA regulates Valnemulin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Valnemulin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Valnemulin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Valnemulin supplier is an individual or a company that provides Valnemulin active pharmaceutical ingredient (API) or Valnemulin finished formulations upon request. The Valnemulin suppliers may include Valnemulin API manufacturers, exporters, distributors and traders.
click here to find a list of Valnemulin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Valnemulin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Valnemulin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Valnemulin GMP manufacturer or Valnemulin GMP API supplier for your needs.
A Valnemulin CoA (Certificate of Analysis) is a formal document that attests to Valnemulin's compliance with Valnemulin specifications and serves as a tool for batch-level quality control.
Valnemulin CoA mostly includes findings from lab analyses of a specific batch. For each Valnemulin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Valnemulin may be tested according to a variety of international standards, such as European Pharmacopoeia (Valnemulin EP), Valnemulin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Valnemulin USP).
LOOKING FOR A SUPPLIER?
